COMMUNIQUÉS West-GlobeNewswire

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
29/07/2026
Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran’s A-SUQAR commercial distribution agreement BOSTON, MASSACHUSETTS, [...]
Anika Reports Second Quarter 2026 Financial Results
29/07/2026
Commercial Channel Revenue Increased 17% to a Record $13.9 Million Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020 Raising Full-Year 2026 Financial [...]
Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease
29/07/2026
Grant supports IND-enabling studies of an intravenously delivered, disease-modifying gene therapy designed to reduce alpha-synuclein in the brain regions most affected by Parkinson’s disease SEATTLE, July 29, 2026 ( [...]
Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France
29/07/2026
28 juillet 2026 Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France Biodexa Pharmaceuticals PLC (NASDAQ : BDRX), une société [...]
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
29/07/2026
RALEIGH, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced it will release its second quarter 2026 financial and [...]
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
29/07/2026
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA ’s U.S. Market Share [...]
Axogen, Inc. Reports Second Quarter 2026 Financial Results
29/07/2026
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million ALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing [...]
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
29/07/2026
141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure [...]
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
29/07/2026
BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
29/07/2026
Medtech Market-Builder Thomas West and Health System Operator Sharon O’Keefe Join Ceribell as Point-of-Care Brain Monitoring Advances Toward Standard of Care SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell [...]
Integra LifeSciences Reports Second Quarter 2026 Financial Results
29/07/2026
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending [...]
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
29/07/2026
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end [...]
XORTX Appoints New Director
29/07/2026
CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
29/07/2026
Actively enrolling patients across the US with anticipated topline data readout mid-2028 WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company [...]
Fortrea Reports Second Quarter 2026 Results
29/07/2026
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2 million Book-to-bill [...]
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
29/07/2026
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 [...]
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
29/07/2026
Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough ~450 total inhalations administered in patients with IPF [...]
Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026
29/07/2026
BANNOCKBURN, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
29/07/2026
HOUSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track designations for [...]

Pages